Zentek Ltd., through its subsidiary Triera Biosciences Ltd., reports initial positive test results for a universal aptamer targeting the highly pathogenic avian influenza H5N1 virus. The breakthrough involves multivalent aptamer technology showing strong binding affinity to the virus’s HA surface protein.63
Key Developments in Aptamer Testing
Lead aptamer candidates demonstrate binding affinity below one nanomolar to the H5 protein, surpassing the performance of aptamers previously used against SARS-CoV-2. These candidates neutralize multiple influenza subtypes by preventing viral entry into cells. In vivo testing begins immediately, with further optimization planned for pre-clinical trials.63
Context of the H5N1 Outbreak
The World Health Organization highlights the ongoing H5N1 outbreak since 2020 as a major concern, with recent spread to U.S. livestock and detection in milk supplies. The virus carries a historical human mortality rate up to 52% and has killed millions of poultry. Officials prioritize solutions to curb transmission to humans and protect food supplies.63
Triera filed a provisional patent for the influenza-targeting aptamer. The company aims to develop an integrated system combining diagnostics, prophylaxis, and therapeutics using the same agent.
Leadership Commentary
“Our aptamer platform has shown robust results with COVID-19 as proof of concept,” states Greg Fenton, CEO of Zentek and Triera. “We are confident in rapidly responding to outbreaks like H5N1.”
Dr. Matthew Miller, Triera advisor and Canada Research Chair in Viral Pandemics, adds, “Triera’s prioritization of avian influenza is sound. This technology could mitigate outbreaks efficiently.”63
About the Companies
Triera Biosciences holds an exclusive 20-year license from McMaster University for aptamer and DNAzyme technologies developed in collaboration with the Li Lab.
Zentek Ltd. (Nasdaq: ZTEK; TSX-V: ZEN) focuses on innovative products via its ZenGUARD™ platform and Triera’s aptamer developments for diagnostics and therapeutics.
